Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Dashyant Dhanak, insider at Incyte
Dashyant Dhanak Insider Alerts

Get notified the next time Dashyant Dhanak buys or sells Incyte stock. Enter your email address below to get our daily insider buying and selling report.

Dashyant Dhanak Insider Information

EVP of Incyte
Dash Dhanak joined Incyte in December of 2018 as Executive Vice President and Chief Scientific Officer. With 30 years of broad pharmaceutical and drug discovery experience, Dr. Dhanak joined Incyte from Janssen Research & Development, where, since 2013, he served as Vice President and Head of Discovery Sciences, leading the organization responsible for supporting and enabling the discovery and preclinical development of novel small molecule therapeutics. Prior to his tenure at Janssen, Dr. Dhanak spent 25 years at GlaxoSmithKline in positions of increased responsibility across multiple disease areas, including his last position as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit.

Dr. Dhanak received a Bachelor of Science in Chemistry from the University of Manchester Institute of Science and Technology and his PhD from the University of London, both in the United Kingdom. He completed his postdoctoral research in natural product synthesis at Northwestern University in Chicago, Illinois.

What is Dashyant Dhanak's net worth?

The estimated net worth of Dashyant Dhanak is at least $1.91 million as of September 8th, 2020. Dr. Dhanak owns 28,971 shares of Incyte stock worth more than $1,905,712 as of December 5th. This net worth estimate does not reflect any other investments that Dr. Dhanak may own. Learn More.

How do I contact Dashyant Dhanak?

The corporate mailing address for Dr. Dhanak and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]

Has Dashyant Dhanak been buying or selling shares of Incyte?

During the last quarter, Dashyant Dhanak has sold $26,713.00 in shares of Incyte stock. Most recently, Dashyant Dhanak sold 389 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $68.67, for a transaction totalling $26,712.63.

Who are Incyte's active insiders?

Incyte's insider roster includes Dashyant Dhanak (EVP), Vijay Iyengar (EVP), Michael Morrissey (EVP), and Wenquing Yao (EVP).

Are insiders buying or selling shares of Incyte?

During the last twelve months, Incyte insiders bought shares 1 times. They purchased a total of 12,925 shares worth more than $1,000,007.25. During the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 78,668 shares worth more than $6,905,426.80. The most recent insider tranaction occured on October, 1st when EVP Dashyant Dhanak sold 389 shares worth more than $26,712.63. Insiders at Incyte own 15.8 % of the company.

Information on this page was last updated on 10/1/2021.

Dashyant Dhanak Insider Trading History at Incyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2021Sell389$68.67$26,712.63View SEC Filing Icon  
9/1/2021Sell388$76.71$29,763.48View SEC Filing Icon  
4/1/2021Sell396$81.57$32,301.72View SEC Filing Icon  
9/8/2020Sell961$88.94$85,471.3428,971View SEC Filing Icon  
5/6/2020Sell961$96.84$93,063.2420,948View SEC Filing Icon  
See Full Table

Dashyant Dhanak Buying and Selling Activity at Incyte

This chart shows Dashyant Dhanak's buying and selling at Incyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incyte Company Overview

Incyte logo
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More

Today's Range

Now: $65.78
Low: $65.21
High: $66.79

50 Day Range

MA: $66.20
Low: $63.34
High: $70.37

2 Week Range

Now: $65.78
Low: $61.91
High: $101.47

Volume

2,573,554 shs

Average Volume

2,200,794 shs

Market Capitalization

$14.53 billion

P/E Ratio

27.29

Dividend Yield

N/A

Beta

0.72
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!